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The transcription factor IRF-4 is necessary for Th17 cell differentiation. In this issue of Immunity, Chen et al.
(2008) show that IRF-4-binding protein is a critical negative regulator of IRF-4 function, regulating production
of the cytokines IL-21 and IL-17.The discovery of T helper 17 (Th17) cells
has markedly advanced our under-
standing on many inflammatory and auto-
immune diseases (Dong, 2008). Elevated
amounts of interleukin-17 (IL-17) and
IL-21 are found in rheumatoid arthritis
(RA), systemic lupus erythematosus, and
psoriasis patients. In addition, blocking
of IL-17 or IL-21 in a mouse model of RA
decreases joint damage and destruction
of cartilages and bones. Given the patho-
genic function of Th17 cell cytokines in
autoimmune disease such as RA, it is
critical to understand the control of Th17
cell differentiation. However, the molec-
ular mechanisms involved in the negative
regulation of Th17 cell differentiation have
not been fully defined. In this issue of
Immunity, Chen et al. describe IRF-
4-binding protein (IBP) as a key factor in
controlling T cell-mediated autoimmunity
(Chen et al., 2008).
Th17 cells produce IL-17, IL-17F, and
IL-22, which together regulate inflamma-
tory responses by tissue cells (Dong,
2008). Th17 cell differentiation in mouse
is initiated by the cytokines TGF-b and
IL-6. In addition, Th17 cells also highly
express IL-21, an autocrine cytokine that
synergizes with TGF-b to induce Th17
cell differentiation (Dong, 2008). STAT3,a transcription factor downstream of IL-6
signaling, is essential for Th17 cell differ-
entiation, possibly via the induction of
two nuclear receptors, RORa and RORgt.
Interestingly, IL-21 expression requires
STAT3 but not RORg (Nurieva et al.,
2007). Another molecule, interferon regu-
latory factor 4 (IRF-4), is also critical for
the generation of Th17 cells, and conse-
quently for the development of experi-
mental autoimmune encephalomyelitis
(EAE), a mouse model of multiple sclerosis
(Brustle et al., 2007). IRF-4-deficient Th
cells fail to differentiate into Th17 cells. In
addition, Irf4/ Th cells exhibit impaired
expression of RORgt (Brustle et al., 2007).
Gupta et al. (2003) identified IRF-
4-binding protein (IBP), which exhibits
marked homology with the protein
SWAP-70. In contrast to SWAP-70, IBP
is highly expressed in T cells and, upon
T cell receptor (TCR) engagement, is
rapidly phosphorylated by the kinase
Lck and recruited to the immunological
synapse (Gupta et al., 2003). The same
group reported that IBP-deficient mice
on C57BL/6 and 129 mixed background
spontaneously developed a lupus-like
syndrome, including the accumulation of
effector and memory T cells and IgG+ B
cells, profound hypergammaglobuline-Immunity 29,mia, and autoantibody production (Fanzo
et al., 2006). Thus, it was proposed that
IBP is required for optimal T cell effector
function, lymphocyte homeostasis, and
the prevention of systemic autoimmunity.
To further determine the preventive role
of IBP in the development of autoimmu-
nity, Chen et al. (2008) backcrossed IBP-
deficient mice on Balb/c background
and then crossed to DO11.10 TCR trans-
genic mice. Chen et al. (2008) observed
that at 7 weeks of age, these mice sponta-
neously developed arthritis characterized
by joint erythema and swelling and
increased titers of autoantibodies such
as rheumatoid factor, collagen II anti-
bodies, and cyclin citrullinated peptide
(CCP) antibodies. Beginning at 3 months
of age, these mice started to die, as
a result of the development of large-
vessel vasculitis. In exploring the mecha-
nisms underlying these fatal disorders
associated with IBP deficiency, Chen
et al. (2008) first examined the possibility
of defective central tolerance. However,
using two models of central tolerance,
they found that spontaneous develop-
ment of arthritis and vasculaties in IBP-
deficient DO11.10 mice was not due to
failure of elimination of autoreactive
T cells in the thymus by negative selection.December 19, 2008 ª2008 Elsevier Inc. 841
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in development and function of regulatory
T cells in these mice. In contrast, they
found that IBP-deficient DO11.10 T cells
were hyporesponsive to high antigenic
doses but hyperresponsive to low doses.
Analysis of 6-week-old IBP-deficient
mice revealed a striking accumulation of
KJ1-26hi T cells displaying effector and
memory phenotype (CD62loCD44hi) with
upregulated expression of CD69 and the
costimulatory molecule inducible T cell
costimulator (ICOS). Transfer of this KJ1-
26hi population of cells into nude Balb/c
mice led to sudden death of recipients.
Thus, the absence of IBP led to abnormal
responsiveness and spontaneous activa-
tion in TCR transgenic cells with patho-
genic effector phenotype. However, the
underlying mechanisms have not been
defined in the current study. Whether
IRF-4 binding is required for the function
of IBP in T cell activation should be ad-
dressed in the future.
Chen et al. (2008) also assessed the role
of IBP in the control of pathogenic func-
tions of effector T cells. They detected
substantially elevated amounts of IL-17
and IL-21 produced by mutant cells
compared to wild-type cells. Interestingly,
enhanced amounts of both cytokines
were detected in the absence of Th17
cell polarizing cytokines (in neutral condi-
tion). Considering that IL-21 not only is
expressed by Th17 cells, but also regu-
lates Th17 cell differentiation, abnormal
production of IL-21 production by IBP-
deficient CD4+ T cells might drive them
toward Th17 cell differentiation. This idea
needs to be confirmed in later studies.
In vivo, elevated amounts of these cyto-
kines were detected in the sera and joints
of arthritic IBP-deficient DO11.10 mice.
Thus, early development of autoimmunity
in IBP-deficient DO11.10 mice correlated
with greatly enhanced production of IL-17
and IL-21.
Given that IBP was originally identified
to interact with the transcriptional factor
IRF-4 and that the latter was involved in
Th17 cell differentiation, the major function
of IBP might be to control IRF-4 transcrip-
tional activity. Chen et al. (2008) performed
genetic analysis and found that enhanced
IL-21 and IL-17 production in IBP mutant
cells was abrogated on an IRF-4-deficient
background. Importantly, the authors
showed that IL-21 expression in wild-
type cells requires IRF-4. Thus, IRF-4
appears to be more important than RORg
in IL-21 expression. The relationship of
IRF-4 and STAT3 would need to be exam-
ined in the future. Moreover, Chen et al.
(2008) reported that IRF-4 could act as
a transactivator of the IL-21 gene
promoter. Thus, absence of IBP leads to
enhanced activation of the IL-21 gene
transcription by IRF-4. The authors further
present the data that IBP and IRF-4 can
physically interact, and this binding is
dependent on carboxyl terminus portion
of IBP.
The current study conclusively demon-
strates that IBP is a critical brake of auto-
immune responses. It acts by two folds:
one is to prevent hyperresponsiveness to
low-affinity TCR engagement, and the
other is to restrict the ability of IRF-4 in
programming Th17 cell differentiation.
However, additional studies need to be
performed to advance our knowledge of
this important regulator. First, what is the
relationship of the above two functions of
IBP in T cells? IBP shares substantial
homology with SWAP-70, a Rac activator.
It remains to be addressed whether IBP
has any activity in regulating the Rac and
Rho family of GTPases, which may conse-
quently influence immunological synapse
formation and activation of p38 and JNK
MAP kinases. Whether this aspect of IBP
function contributes to its regulation on
TCR signaling and Th17 cell differentiation
needs to be understood.
Second, what is the direct function of
IBP in Th17 cell differentiation? The
authors have shown IL-21 as a target of
IRF-4 and IBP. Interestingly, the authors
also found that IBP-deficient T cells ex-
hibited elevated expression of ICOS
in vivo. ICOS is required for the pathogen-
esis of an arthritis model and regulates
IL-17 and IL-21 expression (Dong and
Nurieva, 2003; Nurieva et al., 2008).
Enhanced expression of ICOS in san ro-
que mice has been shown to be associ-
ated with IL-21 expression and develop-
ment of spontaneous lupus and arthritis
(Vinuesa et al., 2005). It would be inter-
esting to test whether the phenotypes of
IBP mutant mice are dependent on
ICOS. This may help understand the initial
trigger of an ICOS-IL-21 circuit that is
pathogenic for autoimmunity.
In addition to Th17 cells, IL-21 is also
produced by follicular helper T (Tfh) cells
and was recently shown to mediate the
differentiation of these cells (Nurieva
et al., 2008; Vogelzang et al., 2008). The
abnormal B cell activation and secretion
of pathogenic autoantibodies seen in IBP
mutant mice may be caused by increased
differentiation and function of Tfh cells. It
is thus important to understand whether
IRF-4 is required for IL-21 expression after
Tfh differentiation and whether this regu-
lation has any importance in pathogen-
esis of antibody-mediated autoimmune
diseases. These studies will greatly enrich
our understanding on Tfh cells, as another
lineage of Th cells that help the humoral
immunity.
In conclusion, the work described by
Chen et al. (2008) provides exciting
insights into the function of IBP as a nega-
tive regulator of TCR signaling to low
doses of antigens and of IRF-4 function
in regulation of proinflammatory cytokines
(Figure 1). Further understanding of IBP
function may shed light on the pathogen-
esis of human autoimmunity, as sup-
ported by the lethal phenotypes associ-
ated with IBP mutation.
Figure 1. IBP Regulates the Ability of IRF-4
to Activate IL-21 Promoter
Evidence presented by Chen et al. (2008) demon-
strated the specific interaction of IBP and IRF-4
in the nucleus. This interaction prevents the
binding of IRF-4 to its target site in the IL-21
promoter. Absence of IBP leads to enhanced tar-
geting of the IL-21 gene promoter by IRF-4, conse-
quently leading to abnormal expression of RORg
and IL-17 and to the development of autoimmunity.
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Since the identification of CD44 as the
principal receptor for the extracellular
matrix (ECM) molecule hyaluronan (HA)
almost 20 years ago (Aruffo et al., 1990),
this protein has puzzled immunologists
by virtue of its manifold, at times seem-
ingly contradictory roles. Widely ex-
pressed on almost all cells of the body, it
serves a broad set of important but
frequently redundant functions in organ
development, tissue repair, hematopoi-
esis, and immune defense. Part of the
vexing complexity of its biology probably
stems from the fact that extensive alterna-
tive splicing of the original transcript and
diverse posttranslational modifications of
the various gene products lead to the
generation of many molecular isoforms
with varying functions that are differen-
tially expressed in different cell types
and at different developmental stages of
the same cell type (Ponta et al., 2003).
Naive T cells, like most cells of the
immune system in their resting states,
express the shortest CD44 splice variant
(called CD44s or CD44h), which does
not confer binding to HA. It is only upon
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al. (2008) report that CD44 critically
hocytes by anchoring cytoskeletal p
entiation that T cells express the CD44v5
isoform and that a fraction of them tran-
siently acquire the capability to bind HA
via CD44 (Lesley et al., 1994). Experi-
mental data have suggested that these
T cells’ binding of HA via CD44 impacts
their migration to inflamed tissues that
are rich in HA by facilitating rolling interac-
tions of blood-borne effector T cells with
the postcapillary endothelium, which
allows for subsequent extravasation (De-
grendele et al., 1997). Such a model of
CD44 as an adhesion receptor of effector
cells targeted for inflamed tissues is in
agreement with the observation that its
genetic deficiency confers only a mild
immunological phenotype in healthy
mice (Schmits et al., 1997) but causes
immune dysfunction in several models of
infectious and inflammatory disease
(Pure´ and Cuff, 2001). However, many
other molecular functions of CD44 have
been described, such as signal transduc-
tion, coreceptor function, organization of
membrane proteins, or binding of matrix
metalloproteases for proteolytic activa-
tion of cytokines and pericellular ECM
degradation. Indeed, a more complex
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contributes to the stabilization of
roteins to the cell membrane at their
role of CD44 in T cell function has already
been heralded, for example, by the finding
that it indirectly supports the role of
another T cell adhesion receptor, the
a4b1 integrin, through the formation of
a bimolecular complex via its cytoplasmic
domain (Nandi et al., 2004). Now Mrass
et al. (2008), by demonstrating that
CD44 also allows effector T cells to stabi-
lize polarity independent of its extracel-
lular domain, and at the same time high-
lighting its optimizing function in the
T cell-mediated elimination of tumors,
open up another exciting facet of CD44.
Mrass et al. (2008) focus on a mouse
model in which the adoptive transfer of
in vitro-primed, ovalbumin-specific cyto-
toxic T lymphocytes (CTLs) facilitates the
near-complete rejection of ovalbumin-
expressing tumors. CTLs genetically defi-
cient in CD44 initially reject these tumors
at the same pace as wild-type CTLs, but
they leave behind larger residual tumors
and allow for accelerated local recur-
rence. Upon careful comparative charac-
terization of CTLs lacking CD44, no
defects with respect to activation and
effector differentiation could be identified.
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